Petros Pharmaceuticals denies fraudulent acquisition press release; reports to Nasdaq

Petros Pharmaceuticals, Inc.

A press release issued July 28, 2022 claiming an acquisition of Petros was fraudulent and not authorized by the company.
Petros confirms it is not a party to any such acquisition and has reported the matter to Nasdaq.
The company urges stakeholders to disregard the false press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.